SHL Stock Overview
Through its subsidiaries, develops, manufactures, and sells a range of diagnostic and therapeutic products and services to healthcare providers worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Siemens Healthineers AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €49.35 |
| 52 Week High | €58.48 |
| 52 Week Low | €41.21 |
| Beta | 0.73 |
| 1 Month Change | 9.69% |
| 3 Month Change | -13.87% |
| 1 Year Change | -6.68% |
| 3 Year Change | -9.68% |
| 5 Year Change | 7.67% |
| Change since IPO | 63.41% |
Recent News & Updates
Siemens Healthineers AG (ETR:SHL) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 11
Is Siemens Healthineers (ETR:SHL) A Risky Investment?
May 01Siemens Healthineers AG's (ETR:SHL) Intrinsic Value Is Potentially 75% Above Its Share Price
Mar 05Recent updates
Siemens Healthineers AG (ETR:SHL) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 11Is Siemens Healthineers (ETR:SHL) A Risky Investment?
May 01Siemens Healthineers AG's (ETR:SHL) Intrinsic Value Is Potentially 75% Above Its Share Price
Mar 05It's Unlikely That Siemens Healthineers AG's (ETR:SHL) CEO Will See A Huge Pay Rise This Year
Feb 12Siemens Healthineers AG's (ETR:SHL) Price Is Out Of Tune With Earnings
Jan 30Siemens Healthineers (ETR:SHL) Has A Pretty Healthy Balance Sheet
Dec 20Siemens Healthineers AG (ETR:SHL) Just Released Its Yearly Results And Analysts Are Updating Their Estimates
Nov 10
Innovative Imaging And Resilient Strategies Propel Future Profit Growth
Nov 07 Siemens Healthineers anticipates EPS growth through margin expansion, operational improvements, and strategic innovations in Imaging and Diagnostics.Earnings Tell The Story For Siemens Healthineers AG (ETR:SHL)
Oct 21Is Siemens Healthineers (ETR:SHL) A Risky Investment?
Jul 22Investors Still Waiting For A Pull Back In Siemens Healthineers AG (ETR:SHL)
Jun 16Shareholder Returns
| SHL | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 4.9% | 4.7% | 0.8% |
| 1Y | -6.7% | -8.9% | 14.6% |
Return vs Industry: SHL exceeded the German Medical Equipment industry which returned -12.1% over the past year.
Return vs Market: SHL underperformed the German Market which returned 14% over the past year.
Price Volatility
| SHL volatility | |
|---|---|
| SHL Average Weekly Movement | 4.0% |
| Medical Equipment Industry Average Movement | 6.3% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in DE Market | 12.9% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: SHL has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: SHL's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 73,100 | Bernd Montag | www.siemens-healthineers.com |
Siemens Healthineers AG, through its subsidiaries, develops, manufactures, and sells a range of diagnostic and therapeutic products and services to healthcare providers worldwide. It operates through four segments: Imaging, Diagnostics, Varian, and Advanced Therapies. The Imaging segment provides magnetic resonance imaging, computed tomography, X-ray systems, molecular imaging, and ultrasound systems.
Siemens Healthineers AG Fundamentals Summary
| SHL fundamental statistics | |
|---|---|
| Market cap | €55.08b |
| Earnings (TTM) | €2.09b |
| Revenue (TTM) | €23.14b |
26.4x
P/E Ratio2.4x
P/S RatioIs SHL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SHL income statement (TTM) | |
|---|---|
| Revenue | €23.14b |
| Cost of Revenue | €14.17b |
| Gross Profit | €8.97b |
| Other Expenses | €6.88b |
| Earnings | €2.09b |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Jul 30, 2025
| Earnings per share (EPS) | 1.87 |
| Gross Margin | 38.77% |
| Net Profit Margin | 9.03% |
| Debt/Equity Ratio | 86.2% |
How did SHL perform over the long term?
See historical performance and comparisonDividends
1.9%
Current Dividend Yield51%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/16 15:50 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Siemens Healthineers AG is covered by 39 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Martin Schnee | AlphaValue |
| Hassan Al-Wakeel | Barclays |
| Scott Bardo | Berenberg |